Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Mar 18;160(6):369-79.
doi: 10.7326/M13-1829.

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study

Vincent Lo Re 3rd, Michael J Kallan, Janet P Tate, A Russell Localio, Joseph K Lim, Matthew Bidwell Goetz, Marina B Klein, David Rimland, Maria C Rodriguez-Barradas, Adeel A Butt, Cynthia L Gibert, Sheldon T Brown, Lesley Park, Robert Dubrow, K Rajender Reddy, Jay R Kostman, Brian L Strom, Amy C Justice
Observational Study

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study

Vincent Lo Re 3rd et al. Ann Intern Med. .

Abstract

Background: The incidence and determinants of hepatic decompensation have been incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone.

Objective: To compare the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART.

Design: Retrospective cohort study.

Setting: Veterans Health Administration.

Patients: 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment-naive.

Measurements: Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage.

Results: The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P < 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients.

Limitation: Observational study of predominantly male patients.

Conclusion: Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race.

Primary funding source: National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: None to report.

Figures

Figure 1
Figure 1
Selection of antiretroviral-treated HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients for inclusion in the study. * HIV infection determined by International Classification of Diseases, Ninth Revision diagnosis codes.
Figure 1
Figure 1
Selection of antiretroviral-treated HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients for inclusion in the study. * HIV infection determined by International Classification of Diseases, Ninth Revision diagnosis codes.
Figure 2
Figure 2
Standardized cumulative incidences of hepatic decompensation, based on competing risk regression analyses. Estimates of the cumulative incidence of hepatic decompensation are reported for each group. a. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected (denoted by solid line) and hepatitis C virus-monoinfected patients (denoted by dotted line). b. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA levels ≥1,000 copies/mL on any HIV RNA test result during follow-up (denoted by dashed line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA <1,000 copies/mL on all HIV RNA test results throughout follow-up (denoted by solid line), and hepatitis C virus-monoinfected patients (denoted by dotted line). c. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts <200 cells/mm3 (denoted by solid line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts ≥200 cells/mm3 (denoted by dashed line), and hepatitis C virus-monoinfected patients (denoted by dotted line). Strata for CD4 cell counts ≥200 cells/mm3 were collapsed into a single plot because these HRs were indistinguishable (see Table 2).
Figure 2
Figure 2
Standardized cumulative incidences of hepatic decompensation, based on competing risk regression analyses. Estimates of the cumulative incidence of hepatic decompensation are reported for each group. a. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected (denoted by solid line) and hepatitis C virus-monoinfected patients (denoted by dotted line). b. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA levels ≥1,000 copies/mL on any HIV RNA test result during follow-up (denoted by dashed line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA <1,000 copies/mL on all HIV RNA test results throughout follow-up (denoted by solid line), and hepatitis C virus-monoinfected patients (denoted by dotted line). c. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts <200 cells/mm3 (denoted by solid line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts ≥200 cells/mm3 (denoted by dashed line), and hepatitis C virus-monoinfected patients (denoted by dotted line). Strata for CD4 cell counts ≥200 cells/mm3 were collapsed into a single plot because these HRs were indistinguishable (see Table 2).
Figure 2
Figure 2
Standardized cumulative incidences of hepatic decompensation, based on competing risk regression analyses. Estimates of the cumulative incidence of hepatic decompensation are reported for each group. a. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected (denoted by solid line) and hepatitis C virus-monoinfected patients (denoted by dotted line). b. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA levels ≥1,000 copies/mL on any HIV RNA test result during follow-up (denoted by dashed line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA <1,000 copies/mL on all HIV RNA test results throughout follow-up (denoted by solid line), and hepatitis C virus-monoinfected patients (denoted by dotted line). c. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts <200 cells/mm3 (denoted by solid line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts ≥200 cells/mm3 (denoted by dashed line), and hepatitis C virus-monoinfected patients (denoted by dotted line). Strata for CD4 cell counts ≥200 cells/mm3 were collapsed into a single plot because these HRs were indistinguishable (see Table 2).
See this image and copyright information in PMC

References

    1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7. - PubMed
    1. Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS) AIDS Patient Care STDS. 2009;23(11):915–23. - PMC - PubMed
    1. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn PA. Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY. J Urban Health. 2011;88(3):507–16. - PMC - PubMed
    1. Raymond HF, Hughes A, O’Keefe K, Stall RD, McFarland W. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. Sex Transm Dis. 2011;38(3):219–20. - PubMed
    1. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054–8. - PubMed

Publication types

MeSH terms